Sugi Predict

Sugi Predict / Compounds / SCHEMBL372065

SCHEMBL372065

SCHEMBL372065

COc1cc2c(Cl)ncnc2cc1OCC1CC2CN(C(=O)OCc3ccccc3)CC2C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 16/20 0.56
▸ EPHA2 P29317 15/20 0.56
▸ EPHB4 P54760 13/20 0.56
▸ ERBB2 P04626 8/20 0.51
▸ FLT1 P17948 9/20 0.48
▸ GAK O14976 1/20 0.46
▸ EPHB6 O15197 1/20 0.46
▸ RIPK2 O43353 1/20 0.46
▸ STK10 O94804 1/20 0.46
▸ MAP4K4 O95819 1/20 0.46
▸ ABL1 P00519 1/20 0.46
▸ EGFR P00533 1/20 0.46
▸ LCK P06239 1/20 0.46
▸ YES1 P07947 1/20 0.46
▸ LYN P07948 1/20 0.46
▸ RET P07949 1/20 0.46
▸ HCK P08631 1/20 0.46
▸ BCR P11274 1/20 0.46
▸ SRC P12931 1/20 0.46
▸ EPHA1 P21709 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10245296 0.91 KDR (0.55) KDREPHA2EPHB4ERBB2FLT1
SCHEMBL372066 0.83 EGFR (0.42) KDREPHA2EPHB4EGFRIRAK4
SCHEMBL372077 0.83 KDR (0.49) KDREPHA2EPHB4ERBB2FLT1
SCHEMBL5143520 0.83 KDR (0.51) KDREPHA2EPHB4ERBB2FLT1
SCHEMBL13787632 0.79 SRC (0.49) KDREPHA2EPHB4SRCTGFBR1
SCHEMBL4401214 0.79 EPHA2 (0.67) KDREPHA2EPHB4ERBB2FLT1
SCHEMBL4402150 0.78 MET (0.47) KDREPHA2EPHB4
SCHEMBL15090477 0.77 KDR (0.44) KDREPHA2EPHB4ERBB2SRC
SCHEMBL371871 0.77 MET (0.47) KDREPHA2EPHB4
SCHEMBL5141863 0.77 KDR (0.48) KDREPHA2EPHB4ERBB2FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US disclosed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US disclosed
EP-3329918-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2018-06-06 — — EP disclosed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US disclosed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US disclosed
EP-2409704-B1 c-Met modulators and methods of use EXELIXIS INC (US) 2017-09-20 — — EP disclosed
US-20160185725-A1 c-Met Modulators and Method of Use EXELIXIS, INC. 2016-06-30 — — US disclosed
US-20160185725-A1 c-Met Modulators and Method of Use EXELIXIS, INC. 2016-06-30 — — US disclosed
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE EXELIXIS, INC (US) 2009-04-23 — — US disclosed
EP-1673085-A4 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2008-12-10 — — EP disclosed
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-10-18 — — US disclosed
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-10-18 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
EP-1673085-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2006-06-28 — — EP disclosed
WO-2005030140-A2 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-04-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET KDR 4/4885EPHA2 610/4885EPHB4 207/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET KDR 4/4885EPHA2 610/4885EPHB4 207/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET KDR 4/4885EPHA2 610/4885EPHB4 207/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET KDR 4/4885EPHA2 610/4885EPHB4 207/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 KDR 5/4885EPHA2 834/4885EPHB4 336/4885
US-20160185725-A1 c-Met Modulators and Method of Use FLT4, MET, FLT1 KDR 5/4885EPHA2 834/4885EPHB4 336/4885
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 KDR 5/4885EPHA2 834/4885EPHB4 336/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET KDR 4/4885EPHA2 610/4885EPHB4 207/4885
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE FLT4, MET, FLT1 KDR 5/4885EPHA2 746/4885EPHB4 329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.